
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
FDA and AstraZeneca have added a boxed warning and strengthened the Warnings section of the Nolvadex (tamoxifen citrate) tablets label to inform healthcare professionals about new risk information. MedWatch Safety Information http://www.fda.gov/medwatch/SAFETY/2002/safety02.htm#nolvad
FDA and AstraZeneca have added a boxed warning and strengthened the Warnings section of the Nolvadex (tamoxifen citrate) tablets label to inform healthcare professionals about new risk information. MedWatch Safety Information






